How does Scripts exclusive pricing work?

A volume-aggregation model raises specific questions a clinic should resolve before building patient pricing around it. Ask whether your portal rate is tied to any minimum order commitment, and what happens to access or pricing if your volume falls below it. Ask whether the rate you see is per SKU or a blended figure across your order mix, since a strong rate on one GLP-1 can mask a weaker one on another. Ask whether rates are fixed or renegotiate as Scripts's network contracts change. And confirm how ancillary costs — shipping, payment processing, any platform fee — interact with the quoted drug rate. Exclusive pricing on the drug line is less meaningful if other line items raise your true landed cost.

The harder issue with any aggregated network model is independent verification. Without public price benchmarks, you cannot check whether the rate you receive reflects competitive market cost. That is not a reason to dismiss the model — aggregate demand can genuinely lower cost — but it is a reason to compare the portal rate against a publicly visible benchmark, which is exactly what a pass-through catalog gives you.

Fizy Health prices the same compounded medications without putting cost behind a network-access or volume gate. It shows resolved per-vial 503A cost on each catalog and cart line before checkout, with a separately disclosed facilitation fee at payment. The drug cost passes through from the assigned 503A partner, so the number you see is the number you pay — visible whether you are a new clinic or a high-volume one, and visible before you complete onboarding.

For clinics still scaling, that removes a chicken-and-egg problem: you do not need to commit volume to unlock a price tier, and you do not need to complete Apply & Verify before you know your cost. You can compare a pass-through per-vial number against any Scripts portal rate on the exact SKUs you order most, and decide based on delivered landed cost rather than a promise of exclusive savings.